3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Inflammatory Breast Neoplasms
1
Glioblastoma
1
COVID-19
1
Adenocarcinoma of Lung
1
Interventions
Temozolomide
94
Radiotherapy
40
Bevacizumab
40
Lomustine
21
Radiation
18
Surgical Procedures, Operative
10
Carboplatin
9
pembrolizumab
8
Nivolumab
8
Carmustine
8
Irinotecan
7
IL13-PE38
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Flucytosine
6
Cyclophosphamide
6
ABT-414
6
vocimagene amiretrorepvec
5
depatuxizumab mafodotin
5
Valacyclovir
5
Drug Therapy
5
veledimex
4
sargramostim
4
enzastaurin
4
NVP-BKM120
4
Gemcitabine
4
Dianhydrogalactitol
4
Chlorotoxin
4
Aminolevulinic Acid
4
verubulin
3
selinexor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioblastoma
×
bemcentinib
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts